Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma
Presented by Brianna Hoffner,(1) MS, ANP-BC, AOCNP®, and Daniel M. Siegel,(2) MD, MS, FAAD, FACMS
(1)University of Colorado Cancer Center, Denver, Colorado; (2)SUNY Downstate Medical Center, Brooklyn, New York
Presenters’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2017;8:244–248 |
© 2017 Harborside Press®
Novel therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique immune-related adverse events.
For access to the full length article, please sign in